Skip to main content

Peer Review reports

From: Prediction of patients with a tumor proportion score > 50% who do not respond to first-line monotherapy with pembrolizumab

Original Submission
29 Sep 2019 Submitted Original manuscript
31 Oct 2019 Reviewed Reviewer Report - Se Hyun Kim
21 Nov 2019 Reviewed Reviewer Report - Eun Joo Kang
19 Dec 2019 Author responded Author comments - Mitsunori Morita
Resubmission - Version 2
19 Dec 2019 Submitted Manuscript version 2
9 Jan 2020 Reviewed Reviewer Report - Se Hyun Kim
9 Jan 2020 Reviewed Reviewer Report - Eun Joo Kang
14 Jan 2020 Author responded Author comments - Mitsunori Morita
Resubmission - Version 3
14 Jan 2020 Submitted Manuscript version 3
22 Jan 2020 Author responded Author comments - Mitsunori Morita
Resubmission - Version 4
22 Jan 2020 Submitted Manuscript version 4
Publishing
27 Jan 2020 Editorially accepted
3 Feb 2020 Article published 10.1186/s12885-020-6582-4

You can find further information about peer review here.

Back to article page